Navigation Links
Diamyd(R) Diabetes Vaccine Receives Approval to Start Phase III Trials in Europe
Date:3/19/2008

Diamyd Medical AB (http://www.omxgroup.com, OMX: DIAM B;

http://www.otcqx.com, OTC: DMYDY)

STOCKHOLM, Sweden, March 19 /PRNewswire-FirstCall/ -- Diamyd Medical (OMX: DIAM B)(OTC: DMYDY)announced today that the Swedish Medical Products Agency (MPA) has approved the Company's application to commence Phase III studies with the therapeutic diabetes vaccine Diamyd(R).

(Logo: http://www.newscom.com/cgi-bin/prnh/20080314/297194 )

"I am extremely glad that we now can offer our recently diagnosed type 1 diabetes patients the possibility to participate also in the European study," says Professor Johnny Ludvigsson, Linkoping, Sweden, Principal Investigator for the study.

Diabetes teams from approximately 20 Swedish pediatric clinics will meet in Linkoping, Sweden on April 4 to go through details for the study, which will comprise 306 new onset type 1 diabetes patients. Diamyd Medical is planning to file clinical trial applications in another 3-4 European countries and include additionally 20 clinics in the study.

"The approval from the Swedish MPA is another important step in the development of Diamyd(R) towards the market," says Elisabeth Lindner, President and CEO of Diamyd Medical. "Last week we received authorization from the FDA to start a parallel Phase III trial in the US, and together with TrialNet's planned study in the US, the interest in Diamyd is strong. We receive daily inquiries from parents of patients wanting to participate in our studies."

http://www.diamyd.com

Disclaimer: This document contains certain statements relating to the progress, timing and completion of our research, development and clinical trials. These statements can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Diamyd Medical undertakes no obligation to publicly update such statements, whether because of new information, future events or otherwise, nor does Diamyd Medical give any guarantees that the statements, given or implied, are correct. This document is a translation from the Swedish original. No guarantees are made that the translation is free from errors.


'/>"/>
SOURCE Diamyd Medical AB (publ)
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. UMDNJ-University Hospital in Newark to Tailor Diabetes Interventions for Low-Income and Minority Groups With Grant From the International Diabetes Federation
2. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
3. Medifast Outperforms American Diabetes Association Diet by Twice the Weight Loss According to Published Study
4. Statement from the American Diabetes Association Related to ACCORD Trial Announcement
5. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
6. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
7. Mayo Clinic Study Finds Further Association Between Diabetes and Pancreatic Cancer
8. Gastric Banding Reverses Impact of Type 2 Diabetes
9. Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
10. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
11. Help! Im Sick. How Do I Handle My Diabetes?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Call and Webcast to Follow Vanda Pharmaceuticals Inc. (Vanda) ... for the fourth quarter of 2016 on Wednesday, February 15, 2017, ... ... ET on Wednesday, February 15, 2017, during which management will discuss ... corporate activities. To participate in the conference call, please dial 1-888-771-4371 ...
(Date:1/19/2017)... , Jan. 19, 2017 Many patients ... for their medication when a pharmacy just a few ... prescription.  To alleviate this problem Medicationdiscountcard.com has ... to see exactly how much their medication will cost ... Made Easy Medicationdiscountcard.com ...
(Date:1/19/2017)... , January 19, 2017 According to a ... cryotherapy is set to witness a CAGR of 6.5% during the ... will continue to be the leading market for cryotherapy ... ... are emphasizing on ensuring affordable and adequate supply of gas in ...
Breaking Medicine Technology:
(Date:1/21/2017)... ... 21, 2017 , ... Salveo for life, a company that distributes an effervescent ... United States as part of its presence to expand its market reach. , Using ... the productions of nasty toxins as a result of drinking alcohol, eliminating those toxins ...
(Date:1/21/2017)... ... 2017 , ... Seamild, the largest manufacturer of oats in China, is now ... founder. As Oat is recognized globally as one of the healthiest cereals, XieQingkui, the ... it is a move to sow the seed of good karma. Buddhism spirit featuring ...
(Date:1/21/2017)... ... January 21, 2017 , ... Pacifica Graduate Institute’s Alumni ... line-up of events for its annual meeting “Coming Home 2017,” an activity-packed weekend ... Home 2017” will be held on Friday January 27 through Sunday, January 29, ...
(Date:1/21/2017)... ... 21, 2017 , ... Santa Rosa Orthopaedics (SRO) is excited ... 167 Lynch Creek Way. The Petaluma office features three comfortable patient exam rooms, ... services and on-site x-ray services. Two multi-specialist orthopaedic surgeons Dr. Neema Pourtaheri ...
(Date:1/21/2017)... ... January 21, 2017 , ... ... Texas Periodontist Dr. Dan Holtzclaw in media for its creos™ line of bone ... performed by Dr. Holtzclaw in which he utilizes creos™ allo.gain™ bone graft for ...
Breaking Medicine News(10 mins):